Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
Oncology and diabetes medications are expected to be major areas of growth.
HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.
AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.
AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns
The FDA granted the drug Priority Review status just last week.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
An NIH study shows possible limit to Lucentis's appeal.
FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.
AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.
Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).
A survey showed patients are not really clear on what causes cancer.
The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.
The label will now include Waldenstrom's macroglubulinemia.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Lawmakers propose allowing pharma companies to share some off-label information
- Apple's ResearchKit: Five Guidelines for Pharma
- Everyday Health buys rare-disease agency Cambridge BioMarketing